Risk threshold | Number recommended for treatment (% of all people) | Number of CVD events (% of all events) | NNT to prevent 1 CVD event* |
---|---|---|---|
Women | |||
20% | |||
QRISK3 | 39219 (7.9%) | 6084 (47.0%) | 25.8 |
CRISK-CCI | 31,811 (6.4%) | 5344 (41.2%) | 23.9 |
10% | |||
QRISK3 | 79,825 (16.1%) | 8849 (68.3%) | 36.1 |
CRISK-CCI | 73,029 (14.8%) | 8542 (65.9%) | 34.2 |
7.5% | |||
QRISK3 | 100,396 (20.3%) | 9718 (75.0%) | 41.3 |
CRISK-CCI | 93,855 (19.0%) | 9498 (73.3%) | 39.5 |
Men | |||
20% | |||
QRISK3 | 48,769 (10.3%) | 7350 (45.1%) | 26.5 |
CRISK-CCI | 41,517 (8.8%) | 6125 (37.6%) | 27.1 |
10% | |||
QRISK3 | 112,632 (23.8%) | 11,620 (71.3%) | 38.8 |
CRISK-CCI | 107,371 (22.7%) | 11,272 (69.1%) | 38.1 |
7.5% | |||
QRISK3 | 143,424 (30.3%) | 12,967 (79.5%) | 44.2 |
CRISK-CCI | 138,352 (29.2%) | 12,703 (77.9%) | 43.6 |